The FDA Just Aired Pharma's Dirty Laundry (All 14 Loads of It)
The FDA just dropped 14 drug rejection letters for the public to read, resuming a transparency push that has Wall Street cheering and small biotechs sweating. After decades of secrecy, the agency's "radical transparency" initiative is reshaping who controls the narrative when a drug fails.
For decades, when the FDA rejected a drug, the rejection letter stayed between the agency and the company. The public never saw it. Investors got whatever spin the company chose to put on it. Doctors had no idea why a promising therapy hit a wall.
That cozy arrangement just ended, again.
After a brief pause triggered by an industry legal challenge, the FDA has resumed publishing Complete Response Letters (CRLs), the detailed documents the agency sends when it refuses to approve a drug. This latest batch: 14 new rejection letters, laid out for anyone with an internet connection to read.
The Breakup Letter You Were Never Supposed to See
Think of a CRL like a breakup text from a very thorough ex. It doesn't just say "we're done." It lists every reason why, sometimes across multiple pages: the clinical trial wasn't convincing enough, the manufacturing facility had problems, the safety data raised red flags, the labeling was wrong.
Historically, these letters were treated as confidential commercial information. FDA regulations at 21 CFR 314.430 explicitly prohibited the agency from even confirming that an unapproved application existed, let alone sharing why it was rejected. Companies controlled the narrative entirely. And they used that control generously: a 2015 analysis found that sponsors omitted roughly 85% of the FDA's safety and efficacy concerns when publicly describing their own rejections.
Let that sink in. Companies were telling investors about one out of every six or seven problems the FDA actually flagged.
How We Got Here
FDA Commissioner Marty Makary launched what the agency called "radical transparency" in July 2025, publishing over 200 historical CRLs in one shot. Most were for drugs that eventually got approved, so the sting was limited. But in September 2025, the agency escalated: it released 89 CRLs for products that were pending, withdrawn, or abandoned, and announced plans to publish new rejection letters in near real-time.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
That's when things got spicy.
An unnamed pharmaceutical company filed a citizen petition challenging the legal basis of the whole program. The company argued that publishing CRLs violated FDA's own confidentiality rules and could expose trade secrets, even after redaction. The petition worked, temporarily. FDA paused the releases around April 2026 while it reviewed the challenge.
But even during that pause, 14 CRLs still made it onto the public database (including letters to companies like Jiangsu and Elevar), suggesting the agency's commitment to transparency was stronger than any procedural speed bump. Now the program appears to be back in full swing.
Wall Street Is Thrilled. Biotech CEOs, Less So.
The investment community's reaction has been, by most accounts, overwhelmingly positive. Equity analysts have described the policy as bringing "a level of accountability and professionalism to a sector that is far from mature." For investors, public CRLs solve a fundamental problem: they no longer have to trust a company's version of events when a drug gets rejected.
The practical benefits are real. Investors can now distinguish between a fixable issue (a labeling dispute or a minor manufacturing tweak) and a fatal flaw (the drug simply didn't work well enough). That distinction matters enormously for valuation. A fixable CRL might delay approval by two months; a fundamental one could kill a program entirely.
Small biotech companies, though, are significantly less enthusiastic. For a company built around a single drug candidate, a public CRL can be devastating. Consider Replimune: its stock plummeted roughly 75% within hours of receiving a CRL for its lead therapy. When your entire company rides on one program, a detailed public autopsy of its regulatory failure is existential.
The Legal Tug-of-War Isn't Over
The citizen petition that triggered the pause highlights a genuine legal tension. FDA's own regulations say the agency shouldn't disclose the existence of an unapproved application unless the sponsor has already gone public with it. Legal experts at firms like Arnold & Porter have argued that publishing certain CRLs "is just not legal" under the current regulatory framework.
FDA has countered by pointing to a Presidential Executive Order (No. 14303) directing agencies to release data and analyses that affect public policy and private-sector decisions. The agency also redacts trade secrets and confidential commercial information before posting, though critics argue that even a redacted letter reveals plenty: the target, the modality, the trial design, the specific ways the program fell short.
This creates a fascinating paradox. Sponsors submitted their applications under decades of assurance that the contents would stay confidential. Changing those rules mid-game, without formal rulemaking, strikes some legal observers as a violation of reliance interests. Others see it as long overdue accountability.
Who Wins, Who Loses
Winners: Investors get faster, more accurate information. Competing drug developers can study rejection letters to avoid the same mistakes. Clinicians gain insight into why therapies failed, which helps them design better trials and counsel patients more effectively. Contract manufacturers can identify recurring FDA concerns and sharpen their services accordingly.
Losers: Small biotechs with vulnerable pipelines face harsher, faster market punishment. Companies with recurring manufacturing or trial design problems now carry visible scars that partners, acquirers, and investors can all see. Some analysts estimate the transparency shift could add 200 to 400 basis points to the effective cost of capital for early-stage, single-asset biotechs; essentially a "transparency tax" on fragile companies.
There's also a subtler risk. If sponsors fear their regulatory correspondence will become public, they might become more guarded in what they share with the agency. That could erode the quality of scientific dialogue between companies and the FDA, which would ultimately hurt patients.
The Bigger Picture
This isn't just about 14 letters. It's about whether the biotech industry operates in sunlight or shadow. For years, companies could fail quietly at the FDA's doorstep and craft their own narrative about what went wrong. That era is ending.
The legal battles will continue. The citizen petition is still unresolved, and the tension between FDA's transparency ambitions and its own confidentiality regulations hasn't been formally reconciled. But the direction is clear: more disclosure, less spin, faster accountability.
For investors, that's a gift. For companies that cut corners on manufacturing, fudge their trial results, or mislead their shareholders about regulatory feedback, it's a reckoning. And for patients waiting on new therapies, it might just mean a system that learns from its failures instead of burying them.
Clinical & Regulatory4 min read
Moderna's Flu Shot Just Cleared Its Biggest Hurdle Yet
Moderna's mRNA flu vaccine just got a unanimous thumbs-up from the FDA's advisory committee. If approved by August 5, it would be the first mRNA flu shot ever licensed in the U.S., opening a multibillion-dollar market that could redefine Moderna's future beyond COVID.
